#MochidaPharmaceuticalCoLtd

Mochida Pharmaceutical Co., Ltd. has set the offering price for common shares at JPY 3,331 per share, with a total offering amount of approximately JPY 3,842.64 million, and an overallotment portion of 173,000 shares totaling approximately JPY 576.26 million. The application period is April 7 to 8, 2026, with the settlement date on April 13.

Mochida Pharmaceutical will acquire the manufacturing and marketing approval of gout and hyperuricemia treatment "Uris Tablets" and related assets from Fuji Pharma Co., Ltd. for 13.5 billion yen, scheduled for execution on June 30, 2026.

Mochida Pharmaceutical Co., Ltd. resolved to conduct a share buyback with an upper limit of 2,000,000,000 yen and 530,000 shares starting May 18, 2026, and to offer 1,153,600 shares through Mitsubishi UFJ Morgan Stanley Securities.

Mochida Pharmaceutical Co., Ltd. has resolved to repurchase up to 530,000 shares with a total upper limit of 2,000,000,000 yen from May 18, 2026, to December 18, 2026.

Consolidated net sales for the third quarter of the fiscal year ending March 2026 were JPY 87,487 million (up 8.4% YoY), operating income was JPY 7,526 million (up 3.9% YoY), and net income attributable to owners of parent was JPY 6,342 million (up 13.2% YoY).